Klotho mRNA Patent EP4711452A2 Published

ChangeBridge: EPO Bulletin - Biotech (C12N)

Published March 18th, 2026

Detected March 24th, 2026

Summary

The European Patent Office published patent application EP4711452A2 on March 18, 2026, related to Klotho messenger-RNA (mRNA) technology. The patent application was filed by ADvantage Therapeutics, Inc. and details specific compositions and sequences for Klotho polypeptides.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4711452A2, detailing a Klotho messenger-RNA (mRNA) composition. The patent, assigned to ADvantage Therapeutics, Inc., specifies the structure of the mRNA, including its 5' CAP region, untranslated regions, a coding region for a Klotho polypeptide with at least 80% sequence identity to SEQ ID NO: 1, and a poly-A tail. It also notes a preferred GC content of at least 54% for the coding region.

This publication represents a new intellectual property filing in the biotechnology sector. While patents do not impose direct compliance obligations on other entities, they establish exclusive rights for the patent holder. Companies operating in the mRNA therapeutics space, particularly those developing Klotho-based therapies, should be aware of this patent's existence and scope to avoid potential infringement issues. No immediate compliance actions are required for entities outside of the patent holder's operations.

Source document (simplified)

← EPO Patent Bulletin

KLOTHO MRNA

Publication EP4711452A2 Kind: A2 Mar 18, 2026

Applicants

ADvantage Therapeutics, Inc.

Inventors

FERNANDEZ SANTANA III, Agustin, HOFFMANN, Thomas, SCHMIDT, Walter

Abstract

The present invention relates to a Klotho messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' un-translated region (5'-UTR), a coding region encoding a Klotho polypeptide, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), wherein the Klotho polypeptide comprises the KL1 domain of human Klotho, preferably wherein the coding region encoding the Klotho polypeptide comprises an RNA sequence having at least 80 % sequence identity to SEQ ID NO: 1, and wherein the coding region encoding the Klotho polypeptide preferably has a GC content of at least 54 %.

IPC Classifications

C12N 9/24 20060101AFI20240927BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →